Genistein

Genistein (C15H10O5) is a naturally occurring compound that structurally belongs to a class of compounds known as isoflavones. It is described as an angiogenesis inhibitor and a phytoestrogen.
It was first isolated in 1899 from the dyer's broom, "Genista tinctoria"; hence, the chemical name. The compound structure was established in 1926, when it was found to be identical with that of prunetol. It was chemically synthesized in 1928. It has been shown to be the primary secondary metabolite of the "Trifolium" species and "Glycine max L".
Natural occurrences.
Isoflavones such as genistein and daidzein are found in a number of plants including lupin, fava beans, soybeans, kudzu, and psoralea being the primary food source, also in the medicinal plants, "Flemingia vestita" and "F. macrophylla", and coffee. It can also be found in "Maackia amurensis" cell cultures.
Biological effects.
Besides functioning as an antioxidant and anthelmintic, many isoflavones have been shown to interact with animal and human estrogen receptors, causing effects in the body similar to those caused by the hormone estrogen. Isoflavones also produce non-hormonal effects.
Molecular function.
Genistein influences multiple biochemical functions in living cells:
Activation of PPARs.
Isoflavones genistein and daidzein bind to and transactivate all three PPAR isoforms, α, δ, and γ. For example, membrane-bound PPARγ-binding assay showed that genistein can directly interact with the PPARγ ligand binding domain and has a measurable Ki of 5.7 mM. Gene reporter assays showed that genistein at concentrations between 1 and 100 uM activated PPARs in a dose dependent way in KS483 mesenchymal progenitor cells, breast cancer MCF-7 cells, T47D cells and MDA-MD-231 cells, murine macrophage-like RAW 264.7 cells, endothelial cells and in Hela cells. Several studies have shown that both ERs and PPARs influenced each other and therefore induce differential effects in a dose-dependent way. The final biological effects of genistein are determined by the balance among these pleiotrophic actions.
Tyrosine kinase inhibitor.
The main known activity of genistein is tyrosine kinase inhibitor, mostly of epidermal growth factor receptor (EGFR). Tyrosine kinases are less widespread than their ser/thr counterparts but implicated in almost all cell growth and proliferation signal cascades.
Redox-active—not only antioxidant.
Genistein may act as direct antioxidant, similar to many other isoflavones, and thus may alleviate damaging effects of free radicals in tissues.
The same molecule of genistein, similar to many other isoflavones, by generation of free radicals poison topoisomerase II, an enzyme important for maintaining DNA stability.
Human cells turn on beneficial, detoxifying Nrf2 factor in response to genistein insult. This pathway may be responsible for observed health maintaining properties of small doses of genistein.
Anthelmintic.
The root-tuber peel extract of the leguminous plant "Felmingia vestita" is the traditional anthelmintic of the Khasi tribes of India. While investigating its anthelmintic activity, genistein was found to be the major isoflavone responsible for the deworming property. Genistein was subsequently demonstrated to be highly effective against intestinal parasites such as the poultry cestode "Raillietina echinobothrida", the pork trematode " Fasciolopsis buski", and the sheep liver fluke "Fasciola hepatica". It exerts its anthelmintic activity by inhibiting the enzymes of glycolysis and glycogenolysis, and disturbing the Ca2+ homeostasis and NO activity in the parasites. It has also been investigated in human tapeworms such as "Echinococcus multilocularis" and "E. granulosus" metacestodes that genistein and its derivatives, Rm6423 and Rm6426, are potent cestocides.
Atherosclerosis.
Genistein protects against pro-inflammatory factor-induced vascular endothelial barrier dysfunction and inhibits leukocyte-endothelium interaction, thereby modulating vascular inflammation, a major event in the pathogenesis of atherosclerosis.
Cancer links.
Genistein and other isoflavones have been identified as angiogenesis inhibitors, and found to inhibit the uncontrolled cell growth of cancer, most likely by inhibiting the activity of substances in the body that regulate cell division and cell survival (growth factors). Various studies have found that moderate doses of genistein have inhibitory effects on cancers of the prostate, cervix, brain, breast and colon. It has also been shown that genistein makes some cells more sensitive to radio-therapy.; although, timing of phytoestrogen use is also important.
Genistein's chief method of activity is as a tyrosine kinase inhibitor. Tyrosine kinases are less widespread than their ser/thr counterparts but implicated in almost all cell growth and proliferation signal cascades. Inhibition of DNA topoisomerase II also plays an important role in the cytotoxic activity of genistein. The observation that transition of normal lymphocytes from quiescence (G0) to the G1 phase of the cell cycle is particularly sensitive to genistein prompted the authors to suggest that this isoflavone may be potential immunosuppressant. Genistein has been used to selectively target pre B-cells via conjugation with an anti-CD19 antibody.
Studies on rodents have found genistein to be useful in the treatment of leukemia, and that it can be used in combination with certain other antileukemic drugs to improve their efficacy.
Estrogen receptor — more cancer links.
Due to its structure similarity to 17β-estradiol (estrogen), genistein can compete with it and bind to estrogen receptors. However, genistein shows much higher affinity toward estrogen receptor β than toward estrogen receptor α.
Data from "in vitro" and "in vivo" research confirms that genistein can increase rate of growth of some ER expressing breast cancers. Genistein was found to increase the rate of proliferation of estrogen-dependent breast cancer when not cotreated with an estrogen antagonist. It was also found to decrease efficiency of tamoxifen and letrozole - drugs commonly used in breast cancer therapy. Genistein was found to inhibit immune response towards cancer cells allowing their survival.
Effects in males.
Isoflavones can act like estrogen, stimulating development and maintenance of female characteristics, or they can block cells from using cousins of estrogen. In vitro studies have shown genistein to induce apoptosis of testicular cells at certain levels, thus raising concerns about effects it could have on male fertility; however, one study found that isoflavones had "no observable effect on endocrine measurements, testicular volume or semen parameters over the study period." in healthy males given isoflavone supplements daily over a 2-month period.
Carcinogenic and toxic potential.
Genistein was, among other flavonoids, found to be a strong topoisomerase inhibitor, similarly to some chemotherapeutic anticancer drugs ex. etoposide and doxorubicin. In high doses it was found to be strongly toxic to normal cells. This effect may be responsible for both anticarcinogenic and carcinogenic potential of the substance. It was found to deteriorate DNA of cultured blood stem cells, which may lead to leukemia. Genistein among other flavonoids is suspected to increase risk of infant leukemia when consumed during pregnancy.
Sanfilippo syndrome treatment.
Genistein decreases pathological accumulation of glycosaminoglycans in Sanfilippo syndrome. "In vitro" animal studies and clinical experiments suggest that the symptoms of the disease may be alleviated by adequate dose of genistein. Genistein was found to also possess toxic properties toward brain cells. Among many pathways stimulated by genistein, autophagy may explain the observed efficiency of the substance as autophagy is significantly impaired in the disease.